GSK plc's drug GSK'227 for extensive-stage small-cell lung cancer received EMA's Priority Medicines (PRIME) designation on December 16, 2024, based on promising clinical data. This designation aims to accelerate its development for patients with significant unmet needs, adding to its previous Breakthrough Therapy designation from the US FDA given in August 2024.